Skip to main content
Premium Trial:

Request an Annual Quote

Distribution Deals Brings Genaltye Maverick Detection System to Europe

NEW YORK (GenomeWeb News) – Genalyte today announced it has inked distribution deals for its Maverick Detection System covering parts of Europe.

The system, which analyzes multiple antibodies and other proteins, also received the CE Mark for research use in Europe.

San Diego-based Genalyte has reached distribution deals with Mokascience in France; Bucher Biotec in Switzerland; and KRD Molecular Technologies in the Czech Republic, Slovakia, and Hungary. The deals are the firm's first in Europe, it noted.

Financial and other terms of the agreements were not disclosed.

The Maverick Detection System uses a silicon chip with arrays of photonic ring sensors, and its workflow can deliver results in as little as 15 minutes from a small volume of sample of various types, Genalyte said.

Martin Gleeson, CSO of Genalyte, said in a statement that the company plans to launch several multiplex assays in the next few months and to announce additional distribution agreements "as we build a distribution network to reach pharmaceutical, biotechnology, and academic researchers around the globe."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.